Zeptronics Diagnostics - A Game Changer in Medical Diagnostics

Intellectual Property

Research and Development Pathway

KMZ Holdings envisions the Zeptronic Diagnostics System to find its place in clinics, doctors’ offices, health centers and hospitals. The Zeptronic COVID-19 Rapid Response Test should be deployed wherever people move into public spaces: between the street and the mall, bus, restaurant, gym, bar.

FDA Approval

FDA approval of a medical test means that data on the test’s effects have been reviewed by the agency, and the test is determined to provide benefits that outweigh its known and potential risks for the intended population. The approval process takes place within a structured framework that includes:

FDA Class 2 diagnostic tests (comprehensive metabolic panel, lipid panel, full urinalysis, blood glucose, hemoglobin A1C, heart rate, blood pressure, oxygen saturation), as well as FDA Class 3 tests, including MRI, CT, ECG, EEG, EMG and for diagnosing such diseases such as HIV and hepatitis B. All tests require approval by national or international governing bodies, such as the FDA in the United States and CE in Europe. Because the Zeptronic Diagnostics System is cloud based, releasing a newly approved test is a function of making it available to specific localities. Similarly, as new disease conditions or novel pathogens appear these too can be qualified and quantified with additional coding.

Eligibility for testing is dependent upon the FDA approvals, and the Company hopes Class 2 tests may take a year, while class 3 tests would take around two years of approval. The Company hopes Covid19 testing approval will be quicker as the FDA views it as exigent circumstances being truly exception to the rule.

Patents

KMZ Holdings holds patents in both India and the United States.

India Patent

US Patent

 Patent Cooperation Treaty (PCT) Patent